Abcam Named AIM Company of the Year
News Oct 14, 2013
Company of the Year is the ultimate accolade for any AIM-listed company. The award is presented to the company that has best demonstrated it is a responsible, fully accountable, dynamic business with strong growth prospects and a commitment to AIM. Above all, the winner is deemed to be a well-managed business, having attracted public funding to enhance and develop its growth potential to the full.
“We’re celebrating 15 years of successful growth at Abcam in 2013, which we credit to a sustainable business model combined with attracting talented employees, who demonstrate exceptional teamwork and a shared passion for providing the best products and services to our customers across the globe,” commented Dr. Jonathan Milner, CEO of Abcam. “This is an exciting time for Abcam as we strive to continue to develop novel solutions to support scientists with their discoveries. I look forward to reporting Abcam’s achievements over the next 15 years.”
Abcam previously won Company of the Year in the 2009 AIM Awards, and has continued to achieve strong growth and shown innovation in the market. The Company has enhanced its product range through the addition of non-primary antibodies, as well as pioneering research tools such as its proprietary rabbit monoclonal antibody technology, RabMAb®, following the acquisition of Epitomics. Abcam’s vision is to become the world’s leading supplier of life science research tools.
With machine learning systems now being used to determine everything from stock prices to medical diagnoses, it's never been more important to look at how they arrive at decisions. A new approach out of MIT demonstrates that the main culprit is not just the algorithms themselves, but how the data itself is collected.